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COMMENTS
ALL ANIMALS ARE EQUAL, BUT SOME ARE
BETTER THAN OTHERS: PATENTING
TRANSGENIC ANIMALS
Ours is a time of intense self-doubt, corroding confidence, and crip-
pling resolve; a time of troubled present and ominous future; a time
of strange clouds and sudden shadows seen in a fading light with
cracking nerve. And hence it is not surprising that so great a tri-
umph as man's discovery of the molecular basis of inheritance
should provoke fear instead of joy, breed suspicion instead of zest,
and spawn the troubled anguish of indecision instead of the proud
relief of understanding.'
R. Sinsheimer
Since the discovery of the structure of DNA by Watson and Crick in
1953, remarkable advances have been made in the field of biochemistry. Sci-
ence has progressed from cracking the genetic code to understanding the
operation and functions of genes. Today, it is possible to splice the genes of
animals and manipulate them to produce essentially a new animal, one with
unique characteristics that would never occur naturally within a particular
species. These expanding capabilities permit refinement of scientific animal
modeling,' a process crucial to progress in medical and genetic research, and
provide future promise for the eradication of diseases such as AIDS and
heart disease.
The popular word in biochemistry today is "transgenic." Transgenic re-
fers to the manipulation and transfer of at least one specific gene sequence
(i.e., a DNA molecule) into the genome4 of a laboratory animal, thus pro-
1. R. SINSHEIMER, ETHICAL ISSUES IN HUMAN GENETICS 341 (1972).
2. Animal modeling is a scientific procedure that causes a laboratory animal to display a
particular human illness or disease. Gene splicing allows a scientist to insert gene(s) into the
laboratory animal which causes that animal to develop a desired human disease, thereby pro-
ducing a convenient model for laboratory investigation. Council on Scientific Affairs, Animals
in Research, 261 J. A.M.A. 3602, 3602-06 (1989) (providing examples and explanations of
animal models in the laboratory).
3. Auerbach, Animal Patenting: Ethics, Enablement and Enforcement, 1989 BIOTECH.
PAT. CONF. WORKBOOK 24, 25 (1989) (publication of the American Type Culture Collection,
12301 Parklawn Drive, Rockville, Maryland 20852, (800) 638-6597).
4. A genome includes all the genes of an organism. There are twenty-three pairs of
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ducing what has been termed a transgenic animal.' On April 12, 1988, the
United States Patent and Trademark Office (PTO) granted its first, and to
date only, transgenic animal patent.6 This transgenic mouse patent is held
by Harvard University 7 and covers the following: "A transgenic non-human
mammal all of whose germ cells and somatic cells contain a recombinant
activated oncogene sequence introduced into said mammal, or an ancestor of
said mammal, at an embryonic stage." 8
Transgene manipulation provides a convenient animal model for scientists
to study more easily certain human cancers. While such experimentation
will undoubtedly benefit mankind, it remains controversial; unanswered eth-
ical and legal questions will continue to accompany the granting of patents
for the new technology.
A United States patent is a property right awarded to an inventor for
seventeen years, giving the inventor the exclusive right to make, use, and sell
the invention in return for the public disclosure of the inventor's procedures
for creating the invention.9 For practical purposes, a patent is essentially an
exchange between an inventor and the American public. In return for the
grant of exclusivity, the inventor publicly discloses the discovery or inven-
tion, as well as the formula for its creation. This system encourages research
and development by inducing inventors to invest in experimentation and in-
chromosomes in a human being-all the genes necessary for humans to function are included
twice within the human being. Each set of genes is called a haploid set of chromosomes. The
genome, then, is one full set of genes within a haploid complement of chromosomes. R. WAL-
LACE, J. KING & G. SANDERS, BIOLOGY: THE SCIENCE OF LIFE 1084 (1981) [hereinafter THE
SCIENCE OF LIFE].
5. Barinaga, Making Transgenic Mice: Is It Really That Easy?, 245 Sci. 590, 590, 591
(1989) [hereinafter Making Transgenic Mice]. The most common method for producing trans-
genic animals is the microinjection method. This procedure involves the removal of fertilized
eggs from an animal and the injection of foreign DNA containing the desired gene(s) sequence
into the nucleus of each egg with a super-fine needle. These eggs are then surgically implanted
into surrogate mothers for development. This labor-intensive technique requires very special-
ized equipment and is both expensive and difficult to master. Id. at 590. Transgenic technol-
ogy differs from conventional, classical breeding methods for producing animals with desired
traits because there is an added "capacity ... to introduce and express a heterologous gene
sequence (i.e., one not derivable from the same species as the transgenic animal) in a second
animal." Auerbach, supra note 3, at 25 (emphasis in original).
6. U.S. Pat. No. 4,736,866 (1988).
7. The mice were developed by Philip Leder and Timothy Stewart, of Harvard Univer-
sity and Genentech, respectively. Id.
8. U.S. Pat. No. 4,736,866 (1988). An oncogene is a cancer-producing gene.
The first "oncomice" . . . carry the ras oncogene, which has been shown to be com-
mon in a variety of human cancers, plus a mouse mammary tumor virus promoter
which ensures that the oncogene is activated in breast tissue so that the mice develop
a human breast cancer within a few months of birth.
Anderson, Oncomouse Released, 336 NATURE 300, 300 (1988).
9. A patent does not necessarily confer the right to sell. 35 U.S.C. § 154 (1982).
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vestigation.'0 The patent-granting power vested in Congress"' has been
passed to the United States Patent and Trademark Office (PTO) through the
enactment of three statutes: the Patent Act of 1790;12 the Plant Protection
Act of 1930;13 and the Plant Variety Protection Act of 1970.1'
The present debate over animal patenting was perhaps best foreshadowed
by Donald J. Quigg, former Commissioner of Patents. In the PTO's
landmark 1987 announcement that it would consider patent applications for
"nonnaturally-occurring non-human multicellular living organisms, includ-
ing animals,"' 5 Quigg asked, "I know I'm not supposed to get on a soapbox,
10. Patentable subject matter is defined as "any new and useful process, machine, manu-
facture, or composition of matter, or any new and useful improvement thereof ... subject to
the conditions and requirements of this title." 35 U.S.C, § 101 (1982).
11. U.S. CONST. art. I, § 8 states that Congress shall have the power to "promote the
Progress of Science and the useful Arts, by securing for limited times to Authors and Inventors
the exclusive Right to their respective Writings and Discoveries."
12. 35 U.S.C. § 100 (1982).
13. 35 U.S.C. § 161 (1982).
14. 7 U.S.C. §§ 2321-2583 (1982).
15. Nonnaturally Occurring Non-Human Animals Are Patentable Under § 101, 33 PAT.
TRADEMARK & COPYRIGHT J. 663, 664 (1987) [hereinafter Patentable Under § 101]. Former
Commissioner Quigg also stated:
A decision by the Board of Patent Appeals and Interferences in Ex parte Allen, [2]
USPQ [2d 1425] (Bd. App. & Int. April 3, 1987), held that claimed polyploid oysters
are nonnaturally occurring manufactures or compositions of matter within the mean-
ing of 35 U.S.C. 101. The Board relied upon the opinion of the Supreme Court in
Diamond v. Chakrabarty, 447 U.S. 303, 206 USPQ 193 (1980)[;] as it had done in Ex
parte Hibberd, 227 USPQ 443 (Bd. App. & Int., 1985), as controlling authority that
Congress intended statutory subject matter to "include anything under the sun that is
made by man." The Patent and Trademark Office now considers nonnaturally oc-
curring non-human multicellular living organisms, including animals, to be patenta-
ble subject matter within the scope of 35 U.S.C. 101.
The Board's decision does not affect the principle and practice that products found
in nature will not be considered to be patentable subject matter under 35 U.S.C. 101
and/or 102. An article of manufacture or composition of matter occurring in nature
will not be considered patentable unless given a new form, quality, properties or
combination not present in the original article existing in nature in accordance with
existing law. See e.g., Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 76
USPQ 280 (1948); American Fruit Growers v. Brogdex, 283 U.S. 1, 8 USPQ 131
(1931); Ex parte Grayson, 51 USPQ 413 (Bd. App. 1941).
A claim directed to or including within its scope a human being will not be consid-
ered to be patentable subject matter under 35 U.S.C. 101. The grant of a limited, but
exclusive property right in a human being is prohibited by the Constitution. Accord-
ingly, it is suggested that any claim directed to a non-plant multicellular organism
which would include a human being within its scope include the limitation "non-
human" to avoid this ground of rejection. The use of a negative limitation to define
the metes and bounds of the claimed subject matter is a permissible form of expres-
sion. In re Wakefield, 422 F.2d 897, 164 USPQ 636 (CCPA 1970).
Accordingly,. the Patent and Trademark Office is now examining claims directed
to multicellular living organisms, including animals. To the extent that the claimed
1991]
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but how can anybody say this kind of development is unethical or wrong?" 16
Today, the granting of patents for genetically engineered animals involves
not only ethical and legal issues, but also presents economic and environ-
mental concerns.
17
As a federal agency, the PTO possesses the power to establish rules and
policies, yet many question its authority to enact a rule with such complex
and far-reaching consequences."8 The decision to allow patents for the
transgenic products of biotechnology is fraught with yet unfathomable com-
plexities. Therefore, it is neither appropriate nor wise to reach a final deter-
mination on the animal patenting issue until after these complexities have
been contemplated and deliberated exhaustively.' 9
This Comment will discuss the practical uses of transgenic animals in ge-
netic research, medicine, and agriculture. It will also describe the issues as-
sociated with patenting higher organisms, such as farm animals and
laboratory mice, and suggest the possible ramifications of this procedure.
Further, this Comment will explain how the PTO and the Supreme Court
have arrived at the conclusion that transgenic animals are patentable subject
matter. Finally, it will explore the void in current legislation, the status of
congressional efforts in this area, and the need for a moratorium to both halt
the granting of animal patents and extend indefinitely the time for a final
resolution of transgenic animal patenting.
I. EVOLUTION OF THE TRANSGENIC ANIMAL: PRACTICAL USES OF
TRANSGENIC ORGANISMS
Deoxyribonucleic acid (DNA),2 ° the genetic material of almost all orga-
subject matter is directed to a non-human "nonnaturally occurring manufacture or
composition of matter-a product of human ingenuity" (Diamond v. Chakrabarty),
such claims will not be rejected under 35 U.S.C. 101 as being directed to nonstatu-
tory subject matter.
Commissioner's Notice of Apr. 7, 1987, 1077 OFF. GAZ. PAT. OF. 24 (Apr. 21, 1987).
16. Patentable Under § 101, supra note 15, at 664; U.S. CONG., OFFICE OF TECHNOLOGY
ASSESSMENT, NEW DEVELOPMENTS IN BIOTECHNOLOGY: PATENTING LIFE-SPECIAL RE-
PORT, OTA-BA-370, 125 (Washington, D.C., U.S. Government Printing Office, Apr. 1989).
17. See infra text accompanying notes 47-59 (animal rights); notes 60-76 (agricultural
industry); notes 77-80 (religious concerns); notes 81-85 (environmental concerns); notes 86-93
(humanity).
18. See Animal Legal Defense Fund v. Quigg, 710 F. Supp. 728 (N.D. Cal. 1989) (holding
that in the promulgation of its 1987 rule, the Patent and Trademark Office did not exceed its
authority), dismissed, 900 F.2d 195 (9th Cir. 1990) (case transferred to Fed. Cir.).
19. See generally Transgenic Animal Patent Reform Act of 1989: Hearings on H.R. 1556
Before the Subcomm. on Courts, Intellectual Property, and the Administration of Justice of the
House Comm. on the Judiciary, 101st Cong., 1st Sess. 246 (1989) [hereinafter Hearings on H.R.
1556] (statement of Steven M. Wise, President, Animal Legal Defense Fund, Inc.).
20. See infra note 22.
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nisms,2 1 contains information that directs cellular activity and ultimately de-
termines physical traits. DNA can therefore be characterized as the data
base of an organism. DNA is also responsible for transmitting all of its in-
formation by duplicating itself and passing down identical copies to the next
generation of cells.
The structure of DNA resembles that of a very long and twisted ladder
with thousands to millions of rungs.2 2 Genes, the basic units of heredity, are
segments of each DNA molecule. Most genes contain a "program"2 that
determines the structure of a protein.24 The genetic message in DNA codes
for the particular type of protein to be synthesized and determines when this
synthesis will occur and the amount of the protein to be produced. The
visible result of the genetic program, then, is a protein responsible for a par-
ticular characteristic of any given organism, including hair color, physical
capacities, and intelligence.
Genetic engineering of transgenic organisms is accomplished by the trans-
fer of genes from one organism into another.25 By manipulating genes in
this way, new organisms may be created and endowed with the novel traits
or unique capabilities that a scientist has 'specifically chosen to produce in
21. THE SCIENCE OF LIFE, supra note 4, at 1080 (DNA not genetic material for RNA
viruses); see infra note 23 (general discussion of RNA).
22. The basic unit of DNA is called a nucleotide which consists of a phosphate, a 5-
carbon sugar (deoxyribose), and one of four different nucleotide bases: thymine, cytosine, ade-
nine, or guanine. DNA is composed of two long chains of nucleotides. The backbone of each
chain consists of alternating sugars and phosphates. The nucleotide bases are like the rungs of
a ladder that hold the two backbones together. Each rung consists of two nucleotide bases
paired together, one from each side of the chain. The structure of the bases allows guanine to
pair only with cytosine, and thymine to pair only with adenine. These two strands of DNA are
wound around each other in the double helix configuration. THE SCIENCE OF LIFE, supra note
4, at 183-91 (discussing DNA structure and replication).
23. DNA codes for the production of proteins, but DNA does not make proteins directly.
Instead, DNA synthesizes messenger RNA (mRNA). In a process called transcription, DNA
incorporates the code for the proteins to be synthesized into the mRNA. The mRNA then
carries the code to the nucleus of the cell where the code is deciphered by transfer RNA
(tRNA) in a process called translation. In translation, amino acids are assembled to make the
proteins originally coded for by the DNA. Id. at 202-17 (discussing transcription and
translation).
24. Proteins can be enzymes, hormones, or structural material. Proteins give organisms
their characteristic properties, including color, shape, texture, physical capacities, and many
other vital functions necessary for the organism to exist. Id. at 64-68.
25. Making Transgenic Mice, supra note 5, at 590. A new method of making transgenic
mice, much simpler than the microinjection of foreign genes, may have been found. This
method involves mixing mouse sperm with the DNA of another animal and then artificially
inseminating the mouse with foreign DNA by in vitro fertilization. Many scientists, however,
are skeptical of this new procedure because the results of the one successful experiment have
not yet been duplicated. Barinaga, Gene-Transfer Method Fails Test, 246 SCI. 446, 446 (1989).
For a description of the microinjection method, see supra note 5.
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the recipient organism. Transgenic organisms or animals are specifically
designed to meet certain human needs; for example, they serve important
roles in agriculture, medicine, and genetic research.
A. Agriculture
In the field of agriculture, biotechnologists seek to improve the quality of
livestock by creating larger and leaner animals. Initial transgenic experi-
ments on mice, using genes that code for rat growth hormone, have resulted
in the generation of giant mice.26 Analogous experiments have been done on
sheep and pigs, using human or bovine growth hormone.2 On pigs, trans-
genic experimefitation has resulted in a significant increase in body weight
coupled with a decrease in back fat.28 As a result of this experimentation,
scientists expect to be able to create not only larger and leaner livestock, but
animals with a greater resistance to disease, a higher degree of fertility, and,
in some, an increased dairy production capacity.29 Scientists also expect to
create cows that produce skim milk and chickens that lay low cholesterol
eggs. °
B. Medicine
Transgenic animals are also used to produce important medicinal proteins
such as human insulin for the treatment of diabetes,3 human growth hor-
mone for people with growth hormone deficiencies, and tissue plasminogen
activator, which is used to break up potentially dangerous blood clots that
form after heart attacks or strokes.3 2 The use of one particularly interesting
26. Westphal, Transgenic Mammals and Biotechnology, 3 FED'N AM. SOC'Y FOR EXPERI-
MENTAL BIOLOGY J. 117, 118 (1989).
27. Id. Opponents to the use of bovine somatotropin (growth hormone) to stimulate milk
production in dairy cows are especially vocal, claiming that the milk produced by the cows is
unsafe for the consumer, the treatment is harmful to the cows, and the overproduction of milk
is detrimental to the dairy farmer. Id.; see also Gibbons, FDA Publishes Bovine Growth Hor-
mone Data, 249 Sci. 852, 852-53 (1990) (discussing the safety of bovine human growth hor-
mone). See generally Hearings on H.R. 1556, supra note 19, at 578 (information on Bovine
Growth Hormone (BGH), supplied by the Foundation on Economic Trends (1989)). While
conceding that dairy farmers may suffer a negative economic impact, see infra text accompany-
ing note 63, proponents claim that the milk is perfectly safe for the consumer because the
composition of the milk produced by the treated cows is no different from that of the untreated
cows. Grossman, Genetic Engineering and the Use of Bovine Somatotropin, 264 J. A.M.A.
1028, 1028 (1990).
28. Westphal, supra note 26, at 118-19.
29. Auerbach, supra note 3, at 28.
30. Gorner & Kotulak, Cattle-Cloning Labs Transform the Barnyard, Chi. Tribune, Apr.
10, 1990, § 1, at 1, col. 2 [hereinafter Cattle-Cloning].
31. Auerbach, supra note 3, at 27.
32. Dibner, Factories of Our Future, 72 CONSUMERS' RES. 15, 15, 16 (1989).
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transgene technique has created animals that produce these medicinal pro-
teins in their milk. This is accomplished by transplanting the genes responsi-
ble for the production of the desired proteins into an animal cell. The
proteins are then produced in great quantity within the animal by the altered
host cell, incorporated into the animal's milk,3" and then separated from the
milk and provided to patients. Presently, the cost of human insulin and tis-
sue plasminogen activator is exorbitant; 34 the transgenic approach offers a
way to produce large quantities of these costly medicines at more affordable
prices. These and other promising medicinal uses3" of transgenic technology
have caused one commentator to describe the experimental animals as phar-
maceutical "factories." 36
Biotechnological production of transgenic animals with human diseases
could expedite the development of a cure for diabetes, AIDS, 7 and some
forms of cancer. 3' Because transgenic animal models frequently provide a
convenient and more affordable device for researchers to study human ill-
nesses at the molecular level, these animals provide a significant contribution
to medical research.
C. Genetic Research
Finally, the study of transgenic animals may someday provide for direct
gene therapy to combat various genetic disorders, including disorders of the
bone marrow, liver, and central nervous system.39 In addition, direct gene
therapy may prevent or cure various types of hormone and enzyme deficien-
cies' ° and serious hemoglobinopathies,4 ' such as sickle cell anemia and
thalassemia.42 In this application, creation of a transgene mutation in a
mouse gene, homologous to the mutation in the affected human gene, would
33. Andrews, Administration Backs Bill on Biotechnology, N.Y. Times, July 28, 1990, § 1,
at 30, col. 5 (late ed.).
34. What Price Mighty Mouse?, NEW REPUBLIC, May 23, 1988, at 7, 10 [hereinafter
Mighty Mouse] (tissue plasminogen activator cost estimated at $2,200 per treatment).
35. The Japanese are currently developing silkworms that produce a hepatitis vaccine. Id.
at 8.
36. Dibner, supra note 32, at 15.
37. Auerbach, supra note 3, at 27; see infra note 93 (discussing potential for gene therapy
to eradicate diseases once believed undefeatable).
38. See Anderson, supra note 8, at 300.
39. Id.
40. Id.
41. Mutations in hemoglobin may result in hemoglobinopathies such as sickle cell anemia
or thalassemia. Westphal, supra note 26, at 120. In these instances, the mutation is genetic
and produces an alteration in the protein structure of the hemoglobin, thus impairing its func-
tions by decreasing its affinity for oxygen or reducing the ability of the hemoglobin to transport
oxygen. J.D. RAWN, BIOCHEMISTRY 142-44 (1983).
42. Westphal, supra note 26, at 120.
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permit scientists to study various human genetic disorders for which current
therapies are inadequate.43
II. THE IMPLICATIONS OF PATENTING LIFE
While the possibilities for advancement in agriculture, farming, and
medicine through the use of transgenic animals seem boundless, opponents
believe this use of biotechnology should be carefully scrutinized.' Members
of animal rights and environmental movements, the agriculture industry,
religious groups, and certain ethicists have all voiced objection to the use of
transgenic animals. Indeed, some believe that biotechnology, if used im-
properly, "has the power to upset the natural order of the world and to
threaten our very humanity.",45 The PTO ruling permitting animal patents
has intensified these concerns. This ruling and the Supreme Court's decision
in Diamond v. Chakrabarty46 have become significant sources of dispute,
spurring a debate so momentous that it has united an unlikely coalition of
farmers, environmentalists, animal welfare activists, and religious leaders.
A. Animal Rights
The genetic engineering of animals has produced an outcry from animal
welfare activists who claim that preventing the suffering of animals out-
weighs the benefits gained from the research. These opponents to animal
patenting raise several arguments. First, they assert that transgene experi-
mentation on animals causes undue animal exploitation.47 Second, they fear
that scientists will disregard animal welfare in their pursuit of patents.48
43. Friedmann, Progress Toward Human Gene Therapy, 244 Sc. 1275, 1275 (1989).
44. Holzman, Biotechnology's New Strain of Strife, INSIGHT, Aug. 31, 1987, at 56.
45. Id.
46. 447 U.S. 303 (1980). The Court's decision, that live organisms are not outside the
scope of patentable inventions, is discussed infra at text accompanying notes 94-100.
47. See Pursel, Pinkert, Miller, Bolt, Campbell, Palmiter, Brinster & Hammer, Genetic
Engineering of Livestock, 244 Sci. 1281, 1285 (1989) [hereinafter Pursel].
48. 134 CONG. REC. S1614 (daily ed. Feb. 29, 1988) (statement of Sen. Hatfield); see also
Pursel, supra note 47, at 1285 ("Although we have been able to stimulate pig growth and
enhance food conversion to protein, it is clear that detrimental effects on the general health of
the pigs were also observed."). However, opponents are not altogether certain that experimen-
tation involving transgenic animals is any more detrimental to the animals involved than those
animals used in nontransgenic experimentation. See generally Council on Scientific Affairs,
Animals in Research, 261 J. A.M.A. 3602 (1989) (overview of the use of animals in scientific
research for the purpose of medical progress); Smith, Loeb, Evans & Hendee, Animals in Re-
search and Testing, 106 ARCHIVES OPHTHALMOLOGY 1184 (1988). One concern of animal
rights groups may be that this new avenue of scientific research has created a greater demand
for experimental laboratory animals. "It is also clear that multigenerational studies are essen-
tial to evaluate the physiological effects of transgenes specifically in pigs and perhaps in all
livestock animals." Pursel, supra note 47, at 1285 (emphasis supplied).
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Third, opponents of transgenic experimentation argue that, "because the
outcome of transgenic experiments is currently unpredictable, animals pro-
duced [from the procedure] will be abnormal at birth, and [will] likely...
develop novel ailments that veterinary medicine will be unable to [cure]." 49
Fourth, opponents argue that the offspring of transgenic animals will suffer
from afflictions similar to those of their parents.
50
Transgenic experimentation has produced abnormalities in research ani-
mals.5 In the genetic engineering of mice, some pathologies include a short-
ened lifespan and infertility. 52 Pathological changes in hogs used for genetic
engineering experimentation commonly include "lethargy, lameness, unco-
ordinated gait, expothalmus, and thickened skin." 3 Other observed detri-
mental effects to hogs include: "gastric ulceration[s], severe synovitis,
degenerative joint disease, pericarditis and endocarditis, cardiomegaly,
parakeratosis, nephritis, and pneumonia. In addition.... [the] boars [lack]
libido." 54
While animal rights activists take a strong stand against animal patenting,
those favoring experimentation on laboratory animals claim that "[w]e long
ago decided that sacrificing animals to science ... is justified."55 These pro-
ponents of animal engineering and animal patenting point out that man has
been creating animals for centuries with classical breeding techniques and
that the concern for animal welfare has never risen in relation to such breed-
ing.56 "Harvard's mouse, the result of a more sophisticated intervention,
49. Taylor, Patenting Life, Cong. Res. Serv., Libr. Congress, Order Code IB87222, at 6
(July 20, 1988).
50. Hearings on H.R. 1556, supra note 19, at 581 (Animal Patenting Fact Sheet submitted
by the Foundation on Economic Trends).
[T]here are at present no models capable of predicting the consequence to an organ-
ism of even the smallest genetic change .... This is the case even when a gene which
specifies a known protein (e.g., growth hormone, insulin) is altered, because it is
virtually impossible" to know in detail all of the interactions in which the changed
protein can participate.
Id. at 588-89 (letter dated Feb. 19, 1988 from Professor Stuart A. Newman, Ph.D., to Con-
gressman Charles Rose).
51. See Pursel, supra note 47, at 1281; see also Ryan, Townes, Reilly, Asakura, Palmiter,
Brinster & Behringer, Human Sickle Hemoglobin in Transgenic Mice, 247 ScI. 566, 566-67
(1990).
52. Pursel, supra note 47, at 1284.
53. Id.
54. Id.
55. Mighty Mouse, supra note 34, at 9.
56. Taylor, supra note 49, at 7. A patent would not be awarded to a particular breed of a
species that was improved by a human's use of classical breeding techniques. A patent will be
awarded only for an invention that would never occur naturally. Therefore, when a scientist
alters the genome of an animal by inserting a human gene, this scientist may be awarded a
patent because the result is one that would never occur naturally within the species.
1991]
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doesn't carry us into a new moral realm."" In addition, proponents point
out that the legislative restraints on animal research do not exclude the use
of animals for some transgenic research.58 Furthermore, proponents argue
that transgenic experimentation may ultimately benefit animals by protect-
ing them from disease.59
B. Agricultural Industry
The agricultural industry will probably face the heaviest economic impact
from transgenic experimentation.6' Presently, there are no patents on farm
animals. However, it is likely that superior farm animals will be produced in
the future through the transgenic process. 6 Farmers who oppose the pat-
entability of life argue that the process threatens the survival of the family
farm. Family farmers unable to afford the new technology would be forced
out of business, conceivably allowing well-funded corporations to monopo-
lize the agriculture industry.62 For instance, the Wisconsin Family Farm
Defense Fund, Inc. and the Farmers Union fear that if bovine growth hor-
mone becomes more available through the use of transgenic animals, each
cow would produce more milk and fewer cows would be needed to satisfy
consumer demand.6" Under these circumstances, the small family farmer
would have difficulty competing in the marketplace:
Even without patented animals the average family farmer in the
United States faces an uncertain future. One congressional study
57. Mighty Mouse, supra note 34, at 9. Scientific exploitation of animals is a longstanding
practice. Animals have suffered in the laboratory and in classical breeding situations through
gene manipulations that produce deformities, mutations, or shortened lifespans. With or with-
out human intervention into the genome of an animal, animals will continue to suffer for the
sake of science.
58. The two mechanisms providing federal oversight of animal research are the Animal
Welfare Act, 7 U.S.C. §§ 2131-2156(h) (1982) (administered by the U.S. Department of Agri-
culture) and the policy of the Public Health Service, outlined in the National Institutes of
Health's Guide for the Care and Use of Laboratory Animals (1985).
59. "[Veterinarians are trying to induce protective traits in mammals. Major targets for
disease resistance include brucellosis, which is blamed for annual cattle losses of at least $168
million .... Other animal ailments under study include blue tongue, foot and mouth disease
and bovine leukemia." Cattle-Cloning, supra note 30, at 14, col. 4.
60. Rifkin, Patenting New Forms of Animal Life: Is Nature Just a Form of Private Prop-
erty?, N.Y. Times, Apr. 26, 1987, § 3, at 2, col. 4.
61. 134 CONG. REC. E2235 (daily ed. June 30, 1988) (statement of Rep. Robert W.
Kastenmeier).
62. See 134 CONG. REC. S1620 (daily ed. Feb. 29, 1988). Opponents believe that "[b]y
extending patent protection to all forms of animals, the Patent Office has provided the chemi-
cal, pharmaceutical and biotechnology companies with the incentive to complete their take-
over of American agriculture," thereby displacing the small family farm. Rifkin, supra note
60, at 2, col. 4.
63. Auerbach, supra note 3, at 32-33.
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has already predicted a loss of 1 million farms as a result of factors
largely separate from biotechnology. The availability of more effi-
cient livestock poses a difficult challenge for the agricultural com-
munity .... [There is already an] existing dairy surplus[] and [we]
must question how much more we need.64
Additionally, unresolved issues such as the timing of royalty payments to
the patentee and the possibility of patent infringement by farm animal breed-
ers and dealers trouble many cattle farmers, dairy farmers, and sheep ranch-
ers. 65 Former Commissioner Quigg has suggested that patentees would be
entitled to royalties from a farmer and that unauthorized breeding of pat-
ented animals, with the intent to increase the numbers of such animals,
would constitute patent infringement under existing patent law.66
It would be difficult, however, to trace the rights of the patentee to enforce
royalty payments because animals, unlike almost any other type of patenta-
ble subject matter,67 reproduce. For instance, if patents presently existed for
farm animals, enforcement of existing patent laws against farmers who pos-
sess these animals would be unfair because it is not certain whether the off-
spring of two transgenic animals would either receive the unique trait of its
parents, merely some degree of the trait, or none of the trait.68 What if the
farmer bred a transgenic animal with a natural animal? Would this be a
patent infringement if the offspring bore the trait? This is one of the unan-
swered questions.69
64. 134 CONG. REC. H7437 (daily ed. Sept. 13, 1988).
65. Rifkin, supra note 60, at 2, col. 4.
66. Schneider, Farmers to Face Patent Fees to Use Gene-Altered Animals, N.Y. Times,
Feb. 6, 1988, at 1, col. 4.
Violation of this [patent] right is a tort analogous to a trespass for which the patent
holder may bring a civil action [(35 U.S.C. § 281 (1982))] in a Federal Court .... In
accordance with general tort theory, liability is also imposed for actively inducing
infringement and for contributory infringement by aiding, abetting, encouraging, or
contributing to direct infringement by another.
R. CHOATE, W. FRANCIS & R. COLLINS, PATENT LAW 583 (3d ed. 1987) (citations omitted).
Remedies for patent infringement include injunctive relief, compensatory damages, and attor-
ney's fees. Id. at 825.
67. In addition to the Patent Act of 1790 (as amended), there are two patent statutes
addressing the subject matter of plants. They are the 1930 Plant Protection Act, 35 U.S.C.
§ 161 (1982) (extending patent protection to certain asexually reproducing plants), and the
Plant Variety Protection Act, 7 U.S.C. §§ 2321-2583 (1982) (enacted in 1970 to provide patent
protection to new varieties of sexually reproducing plants).
68. THE SCIENCE OF LIFE, supra note 4, at 297-316 (discussing patterns of heredity).
69. [A] genetically altered strain of animal is not a single, uniform entity. Biological
variability within any population, even one that is relatively homogeneous geneti-
cally, guarantees that any modification will be expressed in a variety of different ways
in different individuals....
The point of all this is that animals are not built like computers, in which a desired
outcome can be achieved by alterations in a well-ordered program. A group of ani-
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Opponents to animal patenting argue that the agricultural community
does not need livestock patents to provide further incentive and encourage-
ment for improvement within the industry; improved farming efficiency and
productivity has been achieved through classical breeding techniques for
centuries. Furthermore, farmers have been able to successfully produce im-
proved strains of farm animals throughout this time without the incentive of
patents.7 °
On the other hand, proponents of transgenic animal patenting argue that
biotechnology is making farmers obsolete regardless of whether the new
technologies are patented. 7 1 They insist that patents be provided to protect
investments in research and to ensure the ability of the United States to
compete overseas.72 Moreover, "if market concentration in agricultural in-
dustries approaches unhealthy proportions-with or without the aid of pat-
enting-anti-trust law should be vigorously applied. But meanwhile[,] ...
biotechnology . . . [should not be stifled] out of vague fears about big
business.
' 71
Moreover, supporters of the 1987 PTO ruling argue that it would be un-
ethical not to pursue transgenic technology in the agriculture industry.74
Such research offers hope of combatting world hunger by producing animals
capable of being acclimated to harsh environments. 75 Finally, proponents of
animal patenting argue that opponents exaggerate the role of transgenic ani-
mals that carry one or a few altered genes are neither totally identical manufactured
entities, nor predictably different in a consistent manner from all other unmodified
strains. Changes in DNA are generally inherited, but biological properties associated
with such changes are not predictable or necessarily stable.
Hearings on H.R. 1556, supra note 19, at 581 (letter dated Feb. 19, 1988 from Professor Stuart
A. Newman, Ph.D., to Congressman Charles Rose, discussing support for H.R. 3119).
70. Taylor, supra note 49, at 7. The farmer, as a breeder, uses the basic principles of
genetics as a tool to manipulate the genotypes of animals to increase the value of the animals.
Putting inherited superiority to work is a major objective of agricultural research....
Cultivated plants and domesticated animals are known as cultigens. With increasing
precision, man is controlling both the genetics and environments of these culti-
gens .... The genetics of cultigens is not the same as the breeding of cultigens.
Animal and plant breeding involve many arts and sciences relating to cultigens, and
genetics may be considered the most important of these. There are, of course, suc-
cessful breeders who have little or no knowledge of the science of genetics. However,
today's breeder has come to rely on some pretty sophisticated genetic methods...
[for developing new and improved strains of domesticated animals].
J. BREWBAKER, AGRICULTURAL GENETICS 1-2 (1964).
71. Mighty Mouse, supra note 34, at 9.
72. Cattle-Cloning, supra note 30, at 15, col. 4.
73. Mighty Mouse, supra note 34, at 9.
74. See supra note 59 and accompanying text.
75. Taylor, supra note 49, at 7.
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mals in agriculture and that the small farmers' fears are without merit.7 6
C. Religious Organizations
Many religious groups adamantly oppose animal patenting, fearing that
reverence and respect for human life, in fact all life created by God, will be
diminished."' One concern is that when human genes are inserted into ani-
mals, and human characteristics are promulgated throughout the animal
kingdom, the sanctity of human worth will be undermined.7" These same
groups also worry that human and animal life may be regarded as a commer-
cial commodity, a product of industry, or of human manufacture, thereby
undermining the dignity and worth of all life.79 The Religious Leaders
Against Animal Patenting stated that "[t]he gift of life from God, in all its
forms and species, should not be regarded solely as if it were a chemical
product subject to genetic alteration and patentable for economic benefit."'8
Religious leaders opposed to animal patenting are pressuring Congress to
enact measures that will address these concerns.
D. Environmental Concerns
Transgenics create the possibility for serious ecological disruption. Envi-
ronmentalists fear that the release of genetically altered animals into the en-
76. Farm animals differ from experimental animals in that they are raised for eco-
nomic gain. Thus, the cost and time needed to develop transgenic animals must
always be weighed against the anticipated value of the transgenic animals, and the
actual value of currently available animals .... It has been estimated that it would
take three years to produce a small number of transgenic sheep. The cost of the
project, using present technology, has been estimated to be approximately three mil-
lion dollars ....
Although ... impediments [to the production of transgenic farm animals] appear
surmountable, they have and will delay the extension of transgenic genetics to farm
animals. Moreover, alternative, conventional, approaches toward increasing feed ef-
ficiency and milk production have had considerable success (milk production, for
example, per cow has doubled in the past 30 years). This success has provided a
further disincentive to develop techniques for producing transgenic livestock.'
Auerbach, supra note 3, at 28 (citations omitted). Other than cost, impediments to the pro-
duction of transgenic animals include: the technical difficulty in transferring DNA from one
organism to another; the possible incompatibility of transgenic mice experimentation for appli-
cation to farm animals; and the lengthy gestation periods of farm animals in light of the princi-
ples of heredity requiring controlled mating and back-crossing of animals in order to produce
herds of predictably unique offspring. Id.
77. Hearings on H.R. 1556, supra note 19, at 590 (statement of Religious Leaders Against
Animal Patenting).
78. Id.
79. Id.
80. Id.
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vironment will contaminate the native gene pools. 8 1
The effect of species alteration could also impact the delicate bal-
ance of the environment. The creation of new species and the ef-
fect of their release into the environment cannot be completely
predictable, and should be carefully considered. Animals which
are larger and have increased reproductivity could alter the deple-
tion patterns of the ecosystem. Also, if the creation of new im-
proved species leads to the popularization of that animal, valuable
native gene pools could be lost. 2
Depletion of a species' gene pool, one possible consequence of the release
of genetically altered animals into the environment, would decrease the ge-
netic variety and engender a common genetic makeup within a particular
species. Subsequently, the species' resistance would decrease and cause the
species to become susceptible to .an epidemic or widespread disease, ulti-
mately placing the species in a high risk for extinction.
8 3
The release of transgenic animals into the environment gives rise to sev-
eral legal issues. Hypothetically, if a particular genetically engineered and
patented organism must be contained because of a known harm resulting
from its interaction with the environment, should the patentee be responsible
for the consequences of its accidental release into the environment? For in-
stance, "[i]f one of Chakrabarty's [oil-eating] bacteria escaped from his labo-
ratory, can he be held responsible for the mischief it causes? If
Chakrabarty's bacteria find their way into an oil well or an oil-storage tank,
shall he pay drop for drop?"84
In addition, the Humane Society fears that the ownership of wildlife may
become uncertain with the advent of animal patenting."5 If patented trans-
genic animals escaped into the environment, should the patentee have a
81. A gene pool is the aggregate of all the genes possessed by all the members of a particu-
lar population of a species. The frequency of the various genes within a pool may change over
time, randomly, or as a result of mutation or natural selection. This is evolution. In the case
of natural selection, some genes produce traits that increase population survival in a particular
environment, and natural selection facilitates an increased frequency of these certain genes.
Likewise, genes that are not helpful, or that are even detrimental, will be reduced in the gene
pool and may disappear altogether. THE SCIENCE OF LIFE, supra note 4, at 321.
82. 133 CONG. REC. S7268 (daily ed. May 28, 1987) (statement of Sen. Hatfield on pro-
posed amendment to H.R. 1827, a supplemental appropriations bill).
83. In addition, a genetically engineered organism may be at a competitive disadvantage
to an unaltered organism in the same natural environment. Pimentel, Hunter, LaGro,
Efroymson, Landers, Mervis, McCarthy & Boyd, Benefits and Risks of Genetic Engineering in
Agriculture, 39 Biosci. 606, 607 (1989).
84. Kass, Patenting Life, 63 J. PAT. OFF. Soc'Y 570, 598 (1981).
85. Auerbach, supra note 3, at 32.
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rightful claim of ownership to the offspring produced as a result of the trans-
genic animal mating with wildlife?
E. What is Human?
Human beings are not patentable subject matter.16 Yet, one of the meth-
ods used to construct a transgenic animal is to insert human genetic material
into the animal's genome 87 It is unknown whether the resulting hybrid gene
structure places the animal within the definition of "human." For example,
how much human genetic material in an animal would bring that animal
into the confines of humanity? If a fetus is not a human being, would a
transgenic fetus be patentable subject matter?
Steven Wise, President of the Animal Legal Defense Fund, Inc., has con-
sidered this issue extensively. In testimony before a subcommittee of the
House Judiciary Committee, he explained that there is no "fixed genetic defi-
nition of a human being.""8 Indeed, no clearly articulated genetic definition
of a human being exists to date.8 9
86. See supra note 15.
87. Some commentators are repulsed at the notion of producing a creature from the com-
bination of two species--one of them a human being. G. SMITH, THE NEW BIOLOGY: LAW,
ETHICS AND BIOTECHNOLOGY 3 (1989).
There are two central concerns here: the fear that the product would be viewed as an
outcast and not accepted as a member by the species from which it came, and the
fear that inappropriate parts of different species could be combined. More specifi-
cally, it is commonly thought that a creature with a fair amount of human mentality
would be unable to express much if he had a body derived from a wolf or cat.
Id. (footnote omitted).
88. Hearings on H.R. 1556, supra note 19, at 247-48 (statement of Steven M. Wise, Presi-
dent, Animal Legal Defense Fund, Inc.).
The question has been debated for millennia and a human being has been variously
defined as that animal with speech, free will, reason, moral responsibility, thought,
politics, consciousness, morality, the ability to cook or stand on two legs or, as postu-
lated by St. Ambrose, to choose celibacy. Yet every definition has been discarded as
either underinclusive, as some animals, otherwise believed to be human beings, did
not have the relevant characteristic, or overinclusive, as some animals, otherwise be-
lieved to be non-human beings, did.
After tens of thousands of years of experience, human beings have generally been
able to agree who is and who is not another human being essentially by applying a
test similar to that which Justice Stewart used once to identify pornography, which
was "I know it when I see it."
Id. at 248.
89. Id. at 247. An international effort is underway to complete a physical map of the
human genome. The National Institutes of Health's (NIH) National Center for Human Gen-
ome Research is coordinating the genome project in the United States. NIH plans to spend
roughly $200 million a year on three participating centers. "Each [center] will tackle one of
the major objectives of the genome project, such as completing the physical map of one human
chromosome or sequencing a model organism." Briefings, NIH Left Peerless for Genome Cen-
ters, 247 Sci. 1182, 1182 (1990). Although the projected cost of the genome project will be $3
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Because a genetic definition of a human being remains unascertained,
many other crucial questions are unanswerable. For instance, would a
human being result if "[h]uman hybrids or sub-humans... [were] created by
splicing human genetic material with that of a lower animal to produce an
animal-human hybrid?"'  Suppose a human is created through recombinant
DNA technology to be specifically adapted to a particular environment."a If
billion in 15 years, the rewards will be priceless. Alzheimer's, schizophrenia, heart disease,
and cystic fibrosis are among the many diseases that may be eradicated with the completion of
the human genome project. "Other medical applications of a genome sequence include an
early warning system that may help individuals predisposed to diseases such as alcoholism,
colon cancer, and depression." Koshland, Sequences and Consequences of the Human Gen-
ome, 246 Sci. 189, 189 (1989).
Japan is also attempting to solve the intricacies of the human genome through a project
known as the Human Genome Program. The project involves researchers at 30 different insti-
tutions and has five focuses, one of which is human genome analysis. Roberts, Japan Boosts
Genome Research, 246 SCi. 439, 439 (1989). Dangers associated with a map of the human
genome remain controverted:
The potential risks from the new technology gained by sequencing the human gen-
ome appear, on close examination, to be old problems revisited. Genetic counseling
already exists for Down [sic] syndrome, Tay Sachs, and sickle cell anemia. Personal
insurance policies already ask for lung x-rays, heart condition tests, and information
on such behaviors as smoking. Group insurance is available without [such] test[s].
Fingerprints are not required of the general population but are kept on file for those
who commit a crime. The information in the genome adds accuracy and scope to
many of these applications but no new or threatening principles. If the higher visibil-
ity of the genome project causes a qualitative change, then, of course, new procedures
may be needed. [For example if a genome sequence became] a precondition of em-
ployment .... legislation might be needed ....
The argument that dictators would alter genes to convert their enemies' is far-
fetched. The idea that a Hitler or a Stalin would prefer the engineering of Jews into
Aryans or capitalists into communists as cheaper or more satisfying than killing
them (as they did) is absurd. We must be vigilant about ethical concerns but not
paralyzed by outlandish scenarios.
Koshland, supra, at 189. There are, however, those concerned with the use of genetic informa-
tion to discriminate against individuals attempting to obtain education, employment, or insur-
ance. Responding to this concern, Representative John Conyers has suggested protective
federal legislation. Miller, Genetic Privacy Makes Strange Bedfellows, 249 Sc. 1368, 1368
(1990). The following describes a possible piece of legislation
designed to regulate the collection, maintenance, use, and dissemination of genetic
information gathered from individuals by the federal government and its contractors
and grantees. It would forbid agencies to release genetic information without the
individual's written consent, except in the case of a medical emergency ora criminal
investigation where probable cause or reasonable suspicion has been shown. The bill
gives individuals the right to file a suit or [obtain] an injunction against an agency
that has released, or is intending to release, such information without permission. It
also provides criminal penalties for unauthorized release.
Id.
90. Hearings on H.R. 1556, supra note 19, at 248 (statement of Steven M. Wise, President,
Animal Legal Defense Fund, Inc.).
91. Note, Patents on People and the U.S. Constitution: Creating Slaves or Enslaving Sci-
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such a creature is developed, will it be a human being?92 This scenario is not
as far-fetched as it appears, for it may only be a short time before this possi-
bility must be squarely considered. Presently, the National Institutes' of
Health (NIH) is conducting a gene therapy experiment. Recently NIH com-
pleted a human gene transfer experiment. These landmark experiments were
the first of their kind to transfer successfully a foreign gene into the genome
of a human being. Although designed to aid in the development of a promis-
irig cancer treatment, rather than to improve or perfect the human race,
these experiments are man's first attempt to change genetically the human
species.
93
ence?, 16 HASTINGS CONST. L.Q. 221, 222 n.8 (1989) ("Human visitors to a high gravitational
field such as that of Jupiter would fare better if they were short-legged or quadrupedal."). See
generally Comment, The Prospect of Private Unauthorized Eugenics and Ten Feet Tall Basket-
ball Players: A Case of Legislative Oversight?, 1 J. CONTEMP. HEALTH L. & POL'Y 155 (1985)
(discussing the need for a uniform federal statute to regulate and limit a private individual's
attempts to perform human embryo experiments without authorization).
92. Hearings on H.R. 1556, supra note 19, at 244 (proposing the same hypothetical); see
also B. STABLEFORD, FUTURE MAN 108-35 (1984) (chapter, entitled "Engineering People,"
suggests ways of improving the imperfections of the human body via genetic engineering and
also proposes the possibility of adapting man to different living environments, including under-
water or outer space, or for modifying man to be more suitable for war). "Cyborgization" is a
relatively new term used to describe "the integration of biological systems of man's body with
mechanical systems.... [I]f a man could be equipped to link up to machines, he could effec-
tively acquire a whole range of extended selves by being fitted into machines of many different
kinds." G. SMITH, supra note 87, at 4 (emphasis in original) (suggesting that cyborgization
may be an easier means of increasing human capability than the manipulation of human egg
cells).
93. See generally Roberts, Human Gene Transfer Test Approved, 243 Scl. 473 (1989);
Roberts, Ethical Questions Haunt New Genetic Technologies, 243 Sci. 1134 (1989).
The first human gene experiment, involving the transfer of a foreign gene into a human, was
fraught with ethical issues. In a 1989 meeting of the Recombinant DNA Advisory Committee
(RAC) at the NIH, activist Jeremy Rifkin, attempting to force debate on the larger issue of
human genetic engineering and its potential misuse, expressed concern with the implications of
this experiment. "Rifkin accused the RAC of ignoring the social and ethical ramifications of
human gene therapy, essentially saying that the questions this technology raises are too monu-
mental for an 'elite group of NIH scientists and their handpicked ethical consultants'...."
Id. But, in the eyes of the scientific community, this first experiment was a success. It proved
that foreign genes can be introduced safely and expressed in living human beings. Culliton,
Designing Cells to Deliver Drugs, 246 ScI. 746, 746 (1989) [hereinafter Designing Cells].
While the experiment described above cannot technically be called gene therapy because it
involved the use of a foreign gene as a marker and not as a drug, protocols are currently being
submitted to NIH to test real human gene therapy. Culliton, Gene Therapy Proposed, 247 Scl.
1181, 1181 (1990). In September 1990, the first true human gene therapy experiment was
begun and is presently underway. The therapy is designed to give a young child, born without
a functioning immune system, a new immune system. Genetically engineered T-lymphocyte
cells were infused into the child and will continue to be infused for 18 months with the hope
that the cells will be accepted by the patient's body, allowed to produce proper proteins, and
replicate. Many scientists are skeptical and critical of this experiment, claiming that the risks
involved outweigh any possible benefits. They claim that the gene therapy researchers, W.
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III. CHAKRABARTY AND THE 1987 PTO RULING
The justification for the 1987 PTO rule is derived from the 1980 Supreme
Court ruling in Diamond v. Chakrabarty,94 which held that "claims were not
outside the scope of patentable inventions merely because they were drawn
to 'live organisms'. . [and] that a live, human-made microorganism" is
patentable subject matter.",96 Ananda Chakrabarty's oil-consuming bacte-
French Anderson, R. Michael Blaese, and Steven Rosenberg, acted prematurely and were
"driven by ambition and 'not by good science.'" Scientists Criticize Test of Human Gene
Therapy, Wash. Post, Sept. 21, 1990, at A8, col. 2. See generally Culliton, Gene Therapy: Into
the Home Stretch, 249 Sci. 974 (1990) (scientific description of the first human gene therapy
test); Weiss, First Human Gene-Therapy Test Begun, 138 Sci. NEWS 180 (1990) (describing
the first human gene therapy test). But cf Smith, The Promise of Abundant Life: Patenting a
Magnificent Obsession, 8 J. CONTEMP. L. 85, 86 (1982) ("[W]hat has been dismissed as but a
magnificent obsession for power, profits and immortality has in truth a far more intrinsic po-
tential for good and reward for the scientific community and the greater world community.").
Moreover, gene therapy will have direct applications in the field of medicine:
Gene therapy is not just for genetic diseases any more .... The idea of curing
disease by repairing a broken gene is one of the simplest concepts in medicine. At
heart, a gene is nothing more than a chemical set of instructions for the production of
a specialized product. Now that genes are routinely isolated and cloned, it ought to
be simple to replace a broken gene with a whole one-especially in organs such as
blood and bone marrow, which can be easily taken out of the body, modified, and put
back in.
Designing Cells, supra, at 746.
Gene therapy may also prove promising for AIDS patients who need "soluble CD4, the
protein that blocks the AIDS virus from penetrating [the] cells." Id. People who have had
heart attacks and need tissue plasminogen activator (TPA) to prevent artificial blood vessels
from developing clots would also benefit from gene therapy, as would patients with emphy-
sema who need the hormone alpha-I antitrypsin to be delivered to their lungs. In addition,
cancer patients and children with critically weak immune systems that lack of a specific func-
tioning gene would be prime candidates for gene therapy, id., as would cystic fibrosis patients.
Booth, Cystic Fibrosis Finding May Enable Gene Therapy, Wash. Post, Sept. 21, 1990, at A1,
col. 5. See generally Culliton, Gore Tex Organoids and Genetic Drugs, 246 Sdl. 747 (1989);
Culliton, A Genetic Shield to Prevent Emphysema?, 246 ScI. 750 (1989); Culliton, ADA Defi-
ciency: A Prime Candidate, 246 Sci. 751 (1989). For a thorough discussion of the developing
technology of human clonal reproduction and its due process and equal protection ramifica-
tions, see Note, Asexual Reproduction and Genetic Engineering: A Constitutional Assessment of
the Technology of Cloning, 47 S. CAL. L. REV. 476 (1974).
94. 447 U.S. 303 (1980).
95. A microorganism differs from a multicellular organism. A microorganism is very
small, usually consisting of one or a few cells, such as a bacteria, whereas a multicellular
organism, such as a mouse, is comprised of a number of specialized cells. THE SCIENCE OF
LIFE, supra note 4, at 1090.
96. Chakrabarty, 447 U.S. at 304. The ruling of the Supreme Court reversed a decision of
the patent examiner, Sidney A. Diamond, who rejected Chakrabarty's patent claim for an oil-
eating bacteria on the grounds that living things were not patentable subject matter under 35
U.S.C. § 101 (1982). The Court decided that a claim which otherwise satisfies all of the re-
quirements of patentability may not be denied solely on the grounds that the subject of the
claim is living. 447 U.S. at 309, 310, 318. This decision was based upon the Court's broad
interpretation of the following provision of the patent laws: "any new and useful... manufac-
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rium qualified for a patent as a "composition of matter."9 7 In so holding,
the Court distinguished between man-made and naturally occurring, living
and nonliving matter.98 Presented by the petitioner with a parade of hor-
ribles that genetic engineering could one day incite,99 the Court indicated
that it was without competence to decide these arguments: "The choice we
are urged to make is a matter of high policy for resolution within the legisla-
tive process after the kind of investigation, examination, and study that legis-
lative bodies can provide and courts cannot."' 1
In its 1987 announcement, the PTO broadly interpreted the Chakrabarty
opinion, declaring that "[t]o the extent that the claimed subject matter is
directed to a non-human 'nonnatural occurring manufacture or composition
of matter-a product of human ingenuity' ... such claims will not be re-
jected under 35 U.S.C. sec. 101 as being directed to nonstatutory subject
matter." ' This ruling raises the possibility that Congress might similarly
categorize any living organism as a composition of matter.
The terms "manufacture" and "composition of matter" go back to
Jefferson's 1793 patent law, and Congress has retained them with-
out change in all subsequent revisions.... Did Jefferson regard a
living organism as a mere 'composition of matter'? Certainly in
the ordinary sense of these terms, no one should. [The Court] sus-
tains the opinion that Congress intends statutory subject matter to
include "anything under the sun made by man." But if so, why did
Congress in fact make and preserve categorical distinctions among
the kinds of patentable man-made things-processes, machines,
manufactures, and "compositions of matter"-distinctions that
would be unnecessary if "anything under the sun," so long as of
artificial origin, were the sufficient mark of patentable subject mat-
ter-of course, along with novelty, utility, and non-obviousness?
ture, or composition of matter" is the basis upon which a patent is granted. Id. at 307-10
(quoting 35 U.S.C. § 101 (1982)). Because Chakrabarty's invention was not the result of na-
ture's work, but his own, with characteristics differing from any bacteria occurring naturally,
the Court considered the oil-eating bacteria to be patentable subject matter. Id. at 309.
The PTO based its subsequent ruling regarding transgenic animal patenting upon the deci-
sion of the Board of Patent Appeals in Ex parte Allen, 2 U.S.P.Q. 2d (BNA) 1425 (1987). In
Allen, the Board held that a claim for a method of inducing sterility in oysters, satisfying all
other requirements of patentability, would be patentable subject matter under Chakrabarty.
The Board reasoned that the oyster, although a product of nature, was made sterile through a
man-made method for inducing sterility. Id. at 1427.
97. Chakrabarty, 447 U.S. at 308-14 (discussing the Court's reasoning and statutory con-
struction); see supra note 96 (synopsis of Court's ruling).
98. Chakrabarty, 447 U.S. at 314.
99. Id. at 317 (suggesting that genetic research may threaten human race, spread pollu-
tion and disease, result in loss of genetic diversity, and diminish value of human life).
100. Id.
101. Patentable Under § 101, supra note 15, at 664.
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And why . would Congress enact separate plant patent
laws... 102
Currently, more than seventy-five animal patent applications have been
filed with the Patent and Trademark Office"03 and Congress' immediate at-
tention is needed. To grant transgenic animal patents today may result in
the subsequent revocation of such patents if Congress enacts legislation con-
flicting with the PTO rule.
IV. LEGISLATION TAILORED TO THE EMERGING TECHNOLOGY
A. The Need for New Patent Legislation
Because any legislation in this field will haveprofound implications for the
way future generations perceive and value life, all the issues presented above
deserve exhaustive consideration and debate. As technology advances, so
must our patent laws.
Although biotechnology is a new and constantly changing field, the
basis on which one receives a patent is not .... [W]e have reached
the point at which we must examine whether our patent system is
keeping up with technology. Namely, do the truths that have ena-
bled millions of inventors to obtain patents still hold for the patent-
ing of animals? This is a crucial question that needs further
exploration. '4
Thus, in the legislation that will inevitably develop, the following must be
addressed: Will higher organisms remain patentable subject matter? If so,
will the regulation of such inventions be addressed before or after they are
patented? What specifically will not be patentable subject matter? What is
human? What is not human? Will these particular patent applications re-
ceive a higher degree of scrutiny than conventional patents? Who will be
responsible if non-statutory subject matter is patented?
Unlike most other patented technologies, animals are unique because they
reproduce themselves without human intervention. Congress saw the need
to enact legislation responding to a similar situation with plants and created
two patent laws to deal specifically with their unique qualities."°5 Trans-
genic animals deserve the same attention.
102. Kass, supra note 84, at 589-90 (emphasis in original).
103. 135 CONG. REC. E3008 (daily ed. Sept. 12, 1989) (statement of Rep. Cardin).
104. Id.
105. The Plant Protection Act of 1930, 35 U.S.C. § 161 (1982); The Plant Variety Protec-
tion Act of 1970, 7 U.S.C. § 2321-2583 (1982).
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B. Recent Developments in Congress
Congress has been active in its response to the problems presented by
animal patents. On August 13, 1987, Representative Rose introduced H.R.
3119, a bill amending the patent laws to prohibit the patenting of genetically
altered animals for two years."°6 This bill was also designed to revoke any
previously granted patents for transgenic animals. It was defeated in com-
mittee by a 2-to-I vote. 10 7 On February 29, 1988, Senator Hatfield intro-
duced S. 2111 to rescind the rule promulgated by the PTO. He, too,
proposed an amendment to title 35 of the United States Code that would
prohibit the patenting of genetically altered or modified animals and revoke
any previously granted patents.1
0 8
On March 22, 1989, Representative Kastenmeier introduced two bills,
H.R. 1556 and H.R. 1557, that were identical to two bills introduced in the
previous Congress (H.R. 4970, the Transgenic Animal Patent Reform Act,
and H.R. 4971, the Transgenic Animal Regulatory Reform Act). ° H.R.
1557, the Transgenic Animal Regulatory Reform Act, would "regulate the
use of genetically-engineered animals in agricultural activities, and for other
purposes." 110 H.R. 1556 would limit the rights of animal patentees beyond
106. 134 CONG. REC. 23,565 (1988) (statement of Rep. Kastenmeier regarding Rep. Rose's
proposal for a moratorium).
107. Id.
108. S. 2111, 100th Cong., 2d Sess., 134 CONG. REC. 2676-77 (1988).
My decision to offer this legislation is not intended to politicize the Patent Office ....
But the Patent Office itself admits that it does not take ethical or moral considera-
tions into account when assessing an application for a patent. It is, I believe, the
responsibility of Congress to fully consider what kind of technological creativity we
wish to encourage through the patenting process, and I believe the giant leap to
animal patenting provides us with the specific example we need to conduct such a
debate.... This [proposed] moratorium is intended to give Congress the opportunity
to assess the implications of animal patenting.
Id.
109. H.R. 1556 & H.R. 1557, 101st Cong., 1st Sess., 135 CONG. REC. H830 (daily ed. Mar.
22, 1989).
[T]he Transgenic Animal Patent Reform Act addresses the difficult legal and policy
issues that arise from the decision of the Patent and Trademark Office to grant pat-
ents to genetically altered animals ... [and] the Transgenic Animal Regulatory Re-
form Act creates a new regulatory regime for the Federal Government to review
work done with transgenic animals .... [Both] have their roots in measures I spon-
sored last Congress, H.R. 4970 and H.R. 4971, respectively.
Id.
110. H.R. 1557, 101st Cong., 1st Sess., 135 CONG. REC. H380 (daily ed. Mar. 22, 1989)
("[This bill] develops a regulatory approach for the treatment of transgenic animals."). Sec-
tion 101 of the bill establishes a Biotechnology Science Coordinating Committee within the
Office of Science and Technology Policy. The Committee's functions and purposes are to ad-
dress the implications and issues concerning genetically engineered animals. The bill would
require anyone interested in using genetically engineered animals in agricultural activity to
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the restrictions imposed on holders of conventional patents. The bill pro-
vides exemptions to small family farmers, certain larger farmers, and to re-
searchers who reproduce these animals for non-commercial purposes."'1
H.R. 1556, the Transgenic Animal Patent Reform Act, is intended to
serve four basic purposes:
[First, it recognizes that] the Patent Office has determined that ge-
netically altered animals are patentable subject matter. Second, the
bill clarifies that human beings are not patentable subject matter.
Third, the bill authorizes the Commissioner of the Patent and
Trademark Office to issue any regulations necessary to regulate the
deposit of biological materials. Finally,... the bill addresses the
thorny question of the scope of a patent on patented transgenic
farm animals." 2
Some of the critical problems addressed in this Comment have not been
accounted for in H.R. 1556,113 the most significant being the lack of a defini-
tion for what is human or what is not human. Until this question is ad-
dressed, the fear of patenting human life may continue to impede medical
advances in genetic engineering.
On September 12, 1989, Representative Cardin introduced a bill providing
for "a moratorium on the patenting of animal life until there is a proper
regulatory review and approval process in place that takes into consideration
environmental, health, safety and biomedical ethical standards on the com-
obtain a permit from the Secretary of Agriculture. The contents of the permit, including the
restrictions and conditions that a permit may contain, are described in section 202(c) and are
also subject to the discretion of the Secretary. Several categories of animals are exempted,
including genetically engineered animals that are used in biomedical research and that are then
released into the wild under the regulation of the Environmental Protection Agency. The bill
also provides for initial use permits, expanded use permits, commercial use permits, waivers
and extensions of permits, and liabilities and penalties for failure to comply with the bill's
requirements. Id.
111. H.R. 1557, 101st Cong., 1st Sess. (1989). Section 2, entitled Infringement of Patent,
would amend 35 U.S.C. § 271 (1982) by adding the following subsection:
(h)(l) It shall not be an act of infringement for a person whose occupation is farming
to reproduce a patented transgenic farm animal through breeding, use such animal in
the farming operation, or sell such animal or the offspring of such animal.
(2) Notwithstanding the provisions of paragraph (1), it shall be an act of infringe-
ment for a person to sell the germ cells, semen,. or embryos of a patented transgenic
farm animal.
(3) for purposes of paragraphs (1) and (2)-
(A) the term "transgenic farm animal" means a farm animal whose germ cells
contain genetic material originally derived from another animal other than the
parent of the farm animal; and
(B) the term "farm animal" means any animal used or intended for use as food
or fiber.
112. H.R. 1557, 101st Cong., ist Sess., 135 CONG. REC. H830 (daily ed. Mar. 22, 1989).
113. See supra text accompanying notes 86-93.
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mercialization of an animal." ' 4 His bill would put a temporary halt to the
patenting of animals, not out of fear of progress, but out of "concerns about
the effect patenting of animal life could have on our society."l1 5 On Febru-
ary 26, 1990, Senator Hatfield submitted S. 2169 to the Senate for considera-
tion. This bill would amend title 35 of the United States Code to impose a
five-year moratorium on the granting of patents for transgenic animals. The
purpose of the moratorium is to allow Congress time to establish a federal
regulatory process to deal with issues arising in connection with animal pat-
enting. He believes that direct congressional oversight of such far-reaching
technology is critical if Congress is to act responsibly in its representative
capacity. 11
6
At this time, a moratorium is the most appropriate way to address the
problems associated with transgenic animal patenting. Biotechnology has
prompted the imagination of the scientific world and may make hopes for
solving the mysteries of humanity an imminent reality." 7 While Congress'
114. H.R. 3247, 101st Cong., 1st Sess., 135 CONG. REC. E3008 (daily ed. Sept. 12, 1989).
115. Id. Representative Cardin would like to see further exploration of
the implications of animal patenting on our health, safety and environment.... [Ilt
was the PTO, not Congress, that decided in 1987 that nonhuman animals constituted
patentable subject matter. The PTO stepped in to fill the void. But it is time for
Congress to become more involved in the debate. A moratorium would provide us
with the necessary time to determine whether or not we need to make improvements
in our patent law to deal directly with the patenting of animals.
Id.
116. S. 2169, 101st Cong., 2d Sess., 136 CONG. REC. S1611 (daily ed. Feb. 26, 1990). In
addition, Senator Hatfield believes the PTO is incapable of dealing with these issues and that it
is the responsibility of Congress to consider the technology and its ramifications before it dele-
gates any authority to the PTO to do so. His declared intention is not to put a halt to animal
patenting ultimately, but to determine a way to use this new technology responsibly. He noted
that "the patenting of animals blurs the distinction between man's work and God's work in a
way ... [that] is tremendously dangerous." Id. Senator Hatfield addressed economic, envi-
ronmental, ethical and governmental concerns specifically:
In economic terms, this controversial patent policy transforms the genetic makeup of
the biotic community from a common heritage of us all-to the private preserve of
the major corporations. Major biotechnology and chemical corporations will in-
creasingly compete for control and ownership of the gene pool of animal species,
patenting those creatures that they can successfully genetically engineer .... By
genetically altering a major livestock species-and then patenting that creation-a
corporation could become the sole controller of that species. Farmers would be
forced to pay the corporation patent fees every time they bred the species, or sold
part of their herd .... Researchers and small scientific institutions could also be
devastated by animal patenting as they would be forced to pay patent fees on geneti-
cally engineered laboratory animals.
Id. He also discussed other issues associated with animal research, religious convictions, and
the possibility of patenting the human form. Id.
117. See, e.g., Hearings on H.R. 1556, supra note 19, at 593 (statement of Cy Carpenter,
President of the National Farmers Union).
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attention should be directed immediately to this issue, Congress is presently
not ready to resolve the extensive ramifications of animal patenting and a
moratorium would allow for the type of sophisticated deliberation the mat-
ter deserves.
IV. CONCLUSION
Transgenic experimentation may prove to be the key that unlocks the se-
cret of life. Where it takes the scientific world will depend largely on what
limitations are placed upon the scientific and patenting processes by the legal
and scientific professions. The unique problems associated with transgenic
animals are replete with significant legal and ethical obstacles. Before the
question, whether to patent animals, can be answered definitively by Con-
gress, fundamental issues must be resolved. "Such a decision, one that likely
affronts the philosophical, theological, or ethical beliefs of the majority of
Americans, should be made only after the most searching, sensitive, and
comprehensive of debates." '" Certainly, biotechnology will continue to un-
cover the secrets of life with or without patent protection, and there may
come a time when the decision of whether to patent animals appears simplis-
tic. "But Congress should not accelerate the creation and production of
transgenic animals at a time when the debate of these serious issues is just
taking hold, and most of America remains to be informed." ' 9
Diana A. Mark
118. Id. at 256 (statement of Steven M. Wise, President, Animal Legal Defense Fund,
Inc.).
119. Id. (emphasis in original).
